# EDGAR Filing Document

**Accession Number:** 0001061983
**File Stem:** 0000000000-25-007931
**Filing Date:** 2025-7
**Character Count:** 3253
**Document Hash:** 2aca372b5dabc0f8de64d89df5197050
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007931.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0000000000-25-007931

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250729

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYTOKINETICS INC
- **CENTRAL INDEX KEY:** 0001061983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943291317
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 000-50633

**BUSINESS ADDRESS:**
- **STREET 1:** 350 OYSTER POINT BOULEVARD
- **STREET 2:** .
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 624-3000

**MAIL ADDRESS:**
- **STREET 1:** 350 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950170-25-029206

## Text-Extract

```

                                                            July 29, 2025

Sung Lee
Executive Vice President and Chief Financial Officer
Cytokinetics, Inc.
350 Oyster Point Blvd
South San Francisco, CA 94080

       Re: Cytokinetics, Inc.
           Form 10-K for the fiscal year ended December 31, 2024
           File No. 000-50633
Dear Sung Lee:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for the fiscal year ended December 31, 2024
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of
Operations
Results of Operations
Research and Development Expenses, page 46

1.     Please provide revised disclosure to be included in future filings to
break out research
       and development expenses by clinical program or trial. For amounts that
are not
       tracked by program, provide other quantitative or qualitative disclosure
that provides
       more transparency as to the type of research and development expenses
incurred (i.e.
       by nature or type of expense) for each period presented which should
reconcile to total
       research and development expense on the Statements of Operations.
        In closing, we remind you that the company and its management are
responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.
 July 29, 2025
Page 2

      Please contact Vanessa Robertson at 202-551-3649 or Christine Torney at
202-551-
3652 with any questions.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._